159 related articles for article (PubMed ID: 2981616)
1. Antiemetic efficacy of levonantradol compared to delta-9-tetrahydrocannabinol for chemotherapy-induced nausea and vomiting.
Citron ML; Herman TS; Vreeland F; Krasnow SH; Fossieck BE; Harwood S; Franklin R; Cohen MH
Cancer Treat Rep; 1985 Jan; 69(1):109-12. PubMed ID: 2981616
[TBL] [Abstract][Full Text] [Related]
2. Levonantradol: a synthetic cannabinoid in the treatment of severe chemotherapy-induced nausea and vomiting resistant to conventional anti-emetic therapy.
Stuart-Harris RC; Mooney CA; Smith IE
Clin Oncol; 1983 Jun; 9(2):143-6. PubMed ID: 6309451
[TBL] [Abstract][Full Text] [Related]
3. Amelioration of cancer chemotherapy-induced nausea and vomiting by delta-9-tetrahydrocannabinol.
Ekert H; Waters KD; Jurk IH; Mobilia J; Loughnan P
Med J Aust; 1979 Dec; 2(12):657-9. PubMed ID: 231736
[TBL] [Abstract][Full Text] [Related]
4. Double-blind multiple-dose crossover study of the antiemetic effect of intramuscular levonantradol compared to prochlorperazine.
Sheidler VR; Ettinger DS; Diasio RB; Enterline JP; Brown MD
J Clin Pharmacol; 1984 Apr; 24(4):155-9. PubMed ID: 6373843
[TBL] [Abstract][Full Text] [Related]
5. Double-blind comparison of the antiemetic effects of nabilone and prochlorperazine on chemotherapy-induced emesis.
Steele N; Gralla RJ; Braun DW; Young CW
Cancer Treat Rep; 1980; 64(2-3):219-24. PubMed ID: 6250699
[TBL] [Abstract][Full Text] [Related]
6. Levonantradol for the treatment of chemotherapy-induced nausea and vomiting.
Gerhartz HH; Binsack T; Hiller E
Klin Wochenschr; 1983 Jul; 61(14):719-21. PubMed ID: 6350696
[TBL] [Abstract][Full Text] [Related]
7. Antiemetic effect of delta-9-tetrahydrocannabinol in patients receiving cancer chemotherapy.
Sallan SE; Zinberg NE; Frei E
N Engl J Med; 1975 Oct; 293(16):795-7. PubMed ID: 1099449
[TBL] [Abstract][Full Text] [Related]
8. Clinical experience with levonantradol hydrochloride in the prevention of cancer chemotherapy-induced nausea and vomiting.
Heim ME; Romer W; Queisser W
J Clin Pharmacol; 1981; 21(S1):86S-89S. PubMed ID: 7298877
[TBL] [Abstract][Full Text] [Related]
9. Randomized crossover study of the antiemetic activity of levonantradol and metoclopramide in cancer patients receiving chemotherapy.
Heim ME; Queisser W; Altenburg HP
Cancer Chemother Pharmacol; 1984; 13(2):123-5. PubMed ID: 6467496
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of oral granisetron versus oral prochlorperazine in preventing nausea and emesis in patients receiving moderately emetogenic chemotherapy.
Burris H; Hesketh P; Cohn J; Moriconi W; Ryan T; Friedman C; Fitts D
Cancer J Sci Am; 1996; 2(2):85-90. PubMed ID: 9166505
[TBL] [Abstract][Full Text] [Related]
11. Adverse reactions to delta-9-tetrahydrocannabinol given as an antiemetic in a multicenter study.
Devine ML; Dow GJ; Greenberg BR; Holstein DW; Icaza L; Jue PY; Meyers FH; O'Brien E; Roberts CM; Rocchio GL
Clin Pharm; 1987 Apr; 6(4):319-22. PubMed ID: 2822339
[No Abstract] [Full Text] [Related]
12. delta 9-Tetrahydrocannabinol (THC) as an antiemetic in patients treated with cancerchemotherapy; a double-blind cross-over trial against placebo.
Kluin-Neleman JC; Neleman FA; Meuwissen OJ; Maes RA
Vet Hum Toxicol; 1979 Oct; 21(5):338-40. PubMed ID: 516362
[TBL] [Abstract][Full Text] [Related]
13. Antiemetics in patients receiving chemotherapy for cancer: a randomized comparison of delta-9-tetrahydrocannabinol and prochlorperazine.
Sallan SE; Cronin C; Zelen M; Zinberg NE
N Engl J Med; 1980 Jan; 302(3):135-8. PubMed ID: 6985702
[TBL] [Abstract][Full Text] [Related]
14. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America.
Poli-Bigelli S; Rodrigues-Pereira J; Carides AD; Julie Ma G; Eldridge K; Hipple A; Evans JK; Horgan KJ; Lawson F;
Cancer; 2003 Jun; 97(12):3090-8. PubMed ID: 12784346
[TBL] [Abstract][Full Text] [Related]
15. The antiemetic activity of tetrahydrocannabinol versus metoclopramide and thiethylperazine in patients undergoing cancer chemotherapy.
Colls BM; Ferry DG; Gray AJ; Harvey VJ; McQueen EG
N Z Med J; 1980 Jun; 91(662):449-51. PubMed ID: 6250106
[TBL] [Abstract][Full Text] [Related]
16. A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy.
Yeo W; Mo FK; Suen JJ; Ho WM; Chan SL; Lau W; Koh J; Yeung WK; Kwan WH; Lee KK; Mok TS; Poon AN; Lam KC; Hui EK; Zee B
Breast Cancer Res Treat; 2009 Feb; 113(3):529-35. PubMed ID: 18327706
[TBL] [Abstract][Full Text] [Related]
17. Antiemetic efficacy of dexamethasone therapy in patients receiving cancer chemotherapy.
Cassileth PA; Lusk EJ; Torri S; DiNubile N; Gerson SL
Arch Intern Med; 1983 Jul; 143(7):1347-9. PubMed ID: 6347109
[TBL] [Abstract][Full Text] [Related]
18. Nabilone versus prochlorperazine for control of cancer chemotherapy-induced emesis in children: a double-blind, crossover trial.
Chan HS; Correia JA; MacLeod SM
Pediatrics; 1987 Jun; 79(6):946-52. PubMed ID: 3035479
[TBL] [Abstract][Full Text] [Related]
19. Low-dose metoclopramide versus methylprednisolone in controlling chemotherapy induced nausea and vomiting.
Chiara S; Scarsi P; Campora E; Bruzzi P; Tatarek R; Rosso R
Chemioterapia; 1984 Oct; 3(5):333-6. PubMed ID: 6398127
[TBL] [Abstract][Full Text] [Related]
20. Superiority of nabilone over prochlorperazine as an antiemetic in patients receiving cancer chemotherapy.
Herman TS; Einhorn LH; Jones SE; Nagy C; Chester AB; Dean JC; Furnas B; Williams SD; Leigh SA; Dorr RT; Moon TE
N Engl J Med; 1979 Jun; 300(23):1295-7. PubMed ID: 375088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
